Phase 3 clinical trial of Diroximel fumarate for treatment of RRMS yields positive top-line results

recently, the(http://of thecompany of Alkermes and Biogen announced positive top-line resultsa Phase 3 clinicaltrial (http:// for the treatment of recurrent recurrent multiple sclerosis (RRMS)Compared to dimethyl fumarate, the new oral fumarate diroximel fumarate with a unique chemical structure is comparable in efficacy and has better gastrointestinal (gastrointestinal, GI) safety and toleranceAbout Diroximel fumarate
Diroximel fumarate is a precursor to oral fumarateIt can be quickly converted into methylene sulprates in the bodyMomaracid monomethylesters can reduce damage from oxidative stress by activating a transcription factor called Nrf2Diroximel fumarate is currently under review by the u.SFDA(http://and is expected to receive a response in the fourth quarter of this yearon EVOLVE-MS-2
　　EVOLVE-MS-2 is a randomized double-blind, active-controlled, 5-week Phase 3 clinical trial designed to assess GI tolerance, including duration and severity, in PATIENTs with RRMS compared to Tecfidera 　　In this trial, the proportion of patients who withdrew from the trial because of adverse events (AE) was 1.6% in the diroximel fumarate group and 6.0% in the Tecfidera group 　　Of these, the proportion of patients who withdrew from the trial due to GI adverse events was 0.8% in the diroximel fumarate group and 4.8% in the Tecfidera group Data show that the side effects of diroximel fumarate are significantly lower than that of Tecfidera